Pathogenesis of aplastic anemia

Aplastic anemia: pathogenesis and treatment.

Treatment of severe aplastic anemia (SAA) in Europe between 1970 and 1986 is reviewed. 487 patients received an HLA-identical BMT: results are encouraging and currently suggest a 65% survival. However, many patients cannot be offered this procedure because of the absence of an appropriate donor. Forty-five patients were given a non-HLA identical BMT: results are dependent on the degree of misma...

Fas/FasL in the immune pathogenesis of severe aplastic anemia.

Fas/FasL protein expression of bone marrow hematopoietic cells was investigated in severe aplastic anemia (SAA) patients. Fas expression was evaluated in CD34(+), GlycoA(+), CD33(+), and CD14(+) cells labeled with monoclonal antibodies in newly diagnosed and remission SAA patients along with normal controls. FasL expression was evaluated in CD8(+) cells in the same manner. In CD34(+) cells, Fas...

The Immune-mediated Pathogenesis and Treatment of Aplastic Anemia

Aplastic anemia is an immune-mediated disorder in most cases. The suppression of hematopoiesis by CD8+ T cells and also the overproduction of interferon(IFN)-γ and tumor necrosis factor (TNF)-α due to the Th1 response were demonstrated. Aplastic anemia patients with HLA-DRB1*1501 and oligoclonality of the T-cell repertoire in the peripheral blood showed immunosuppressive therapy (IST), cyclospo...

Aplastic Anemia - Diagnos tics and Therapy of Acquired Aplastic Anemia

Aplastic anemia.

PURPOSE OF REVIEW Most acquired aplastic anemia is the result of immune-mediated destruction of hematopoietic stem cells causing pancytopenia and an empty bone marrow, which can be successfully treated with either immunosuppressive therapy or hematopoietic stem-cell transplantation. RECENT FINDINGS In aplastic anemia, oligoclonally expanded cytotoxic T cells induce apoptosis of hematopoietic ...